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Pediatric tumorThe Delta-Notch pathway is an evolutionarily conserved signaling pathway which controls a broad range of
developmental processes including cell fate determination, terminal differentiation and proliferation. In
mammals, four Notch receptors (NOTCH1–4) and ﬁve activating canonical ligands (JAGGED1, JAGGED2,
DLL1, DLL3 and DLL4) have been described. The precise function of noncanonical Notch ligands remains
unclear. Delta-like 1 homolog (DLK1), the best studied noncanonical Notch ligand, has been shown to act
as an inhibitor of Notch signaling in vitro, but its function in vivo is poorly understood. In this review we sum-
marize Notch signaling during development and highlight recent studies in DLK1expression that reveal new
insights into its function.
© 2012 Elsevier B.V. All rights reserved.Introduction
The Delta-Notch pathway is an evolutionarily conserved signaling
pathwaywhich controls a broad range of developmental processes in-
cluding cell fate determination, terminal differentiation and prolifera-
tion [4,5,9]. Notch receptors and ligands are transmembrane proteins
that belong to the Epidermal Growth Factor (EGF)-like family of pro-
teins. Inmammals, four Notch receptors (NOTCH1–4) and ﬁve activat-
ing canonical ligands (JAGGED1, JAGGED2, DLL1, DLL3 and DLL4) have
been described. After ligand binding, Notch receptors release their in-
tracellular domain (NICD), which is cleaved by γ-secretase and then
translocates to the nucleus. The NICD interacts with the DNA-binding
transcriptional repressor C-repeat/DRE Binding Factor 1 (CBF1) also
known as Recombination Binding Protein for immunoglobulin kappa
J region (RBP-J) and converts it into a transcriptional activator that in-
duces transcription of target genes (Fig. 1). In addition to the canonical
ligands, noncanonical ligands can bind to Notch receptors, but the pre-
cise function of these ligands remains unclear. Delta-like 1 homolog
(DLK1), the best studied noncanonical Notch ligand, has been shown
to act as an inhibitor of Notch signaling in vitro [8,74], but its function
in vivo is poorly understood. In this review we summarize Notch sig-
naling during development and highlight recent studies in DLK1 ex-
pression that reveal new insights into its function.tiﬁc Research (NWO); Mosaic
d Intestinal Research, Academic
, The Netherlands. Tel.: +31 20
rs).
l rights reserved.1. The Delta-Notch pathway
1.1. Notch receptors and ligands
The ﬁrstNotch genewas cloned in 1983 and shown to encode a cell-
surface receptor inD.melanogaster [6]. Functional analysis revealed that
Notch is important for cell fate decisions during development of D. mel-
anogaster [7]. Subsequently, two Notch genes (glp-1 and lin-12) were
identiﬁed in C. elegans, whereas four Notch homologs (Notch1–4)
were identiﬁed in vertebrates [101], probably as a result of duplication
events. Phylogenetic analysis of vertebrate Notch genes suggested that
Notch1a and Notch1b (in ﬁsh) resulted from a duplication near the tel-
eost/mammalian divergence [52]. It was further shown that Notch2
appeared in the ﬁrst round of vertebrate duplication events and that
vertebrate Notch2 group is closely related to Notch3 [101]. Notch4 is
found only in mammals and is possibly the result of a rapid divergence
from Notch3 [52].
Five canonical mammalian Notch ligands have been described,
namely JAGGED1, JAGGED2, Delta-like 1 (DLL1), DLL3 and DLL4. Ca-
nonical Notch ligands are characterized by three related structural
motifs: an N-terminal Delta-Serrate-LAG-2 (DSL) domain (a cryptic
EGF-like repeat), specialized tandem EGF-repeats called the DOS do-
main and a variable number of EGF-like repeats (Fig. 2). Notch ligands
can be further classiﬁed on the basis of the presence or absence of a
cysteine-rich domain into the Jagged/Serrate or Delta-like group
(Fig. 2). Both the DSL and the DOS domains are involved in receptor
binding [21,51], but DLL3 and DLL4 are DSL-only ligands.
In addition to the canonical ligands, noncanonical ligands can bind
to Notch receptors. The function of noncanonical ligands is still poorly
understood, but soluble noncanonical ligands may act as dominant-
Fig. 1. Notch intracellular signaling. Schematic representation of the Notch signaling
cascade. Binding of the Notch ligand to the membrane-bound Notch receptor leads to
a sequence of proteolytic events resulting in cleavage of the Notch extracellular domain
by the ADAM17 (also known as TACE) protease, followed by cleavage of the intracellu-
lar domain by γ-secretase [10]. The Notch intracellular domain (NICD) then translo-
cates to the nucleus and binds to the DNA-binding transcriptional repressor CBF1/
RBP-J. This binding converts CBF1 into a transcriptional activator, which leads to tran-
scription of target genes. One of the best characterized Notch target genes is the Hairy
and Enhancer of Split (HES) family of transcriptional repressors which encode for basic
helix-loop-helix (bHLH) DNA-binding proteins [4,9].
Fig. 3. Lateral inhibition. Schematic respresentation of the process of lateral inhibition
by which pluripotent stem cells adopt alternative cell fates. First, an instructive signal
leads to upregulation of the Delta ligand in one cell(the central cell in this scheme;
doubling of Delta ligand expression). This leads to activation of Notch on the neighbor-
ing cell, which in turn results in downregulation of Delta in that same cell, which en-
hances the ﬁrst signal. The divergence between the two cells can then lead to
differentiation into alternative cell fates: the central cell in the scheme initially ex-
presses two delta ligands and two Notch receptors interacting with their right and
lower neighbor cells, which express 1 and 2 Delta ligands, respectively. After an in-
structive signal, Delta becomes upregulated in the central cell, depicted by 5 Delta li-
gands instead of 2, which then leads to downregulation of Delta ligands in its right
and lower neighbor cell, which now express 0 and 1 Delta ligand.
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molog (DLK1) is the best studied noncanonical Notch ligand. It re-
sembles DLL ligands, but misses the DSL domain (Fig. 2) and was
shown to inhibit NOTCH signaling as a DOS co-ligand [8,74].
One of the most prominent features of canonical Delta-Notch sig-
naling is that the ligand-receptor association occurs only between
neighboring cells. This feature becomes accentuated in the process
of “lateral inhibition”, which occurs when two initially identical pro-
genitor cells adopt different cell fates due to upregulation of the
Delta ligand in one cell. This activates the Notch receptor on the
neighboring cell, which in turn results in down regulation of Delta ex-
pression in that same cell, enhancing the divergence between the two
cells [47,57]. These cells can then adopt alternative cell fates (Fig. 3).
1.2. Importance of Delta-Notch signaling during development: loss of
function studies
Knockout studies for each of the mammalian Notch receptors and
ligands have been conducted in mice. Table 1 provides an overview ofFig. 2. Notch Ligands. Schematic representation of the structural organization of Notch
ligands (adapted from Kopan et al. 2009 [51]). Classical Notch ligands contain the DSL
(Delta-Serrate-Lag-2), DOS (Delta and OSM-11-like proteins) and EFG (Epidermal
growth factor) motifs. DLL3 and DLL4 are considered DSL-only ligands. DLK1 is consid-
ered a DOS co-ligand [51].the resulting phenotypes of these Notch pathway knockouts
[26,27,33,40,42,46,53,71,78,98,111].
1.2.1. NOTCH1
Homozygous disruption of the Notch1 gene is fatal around embry-
onic day (ED)10, indicating that Notch1 is essential for normal embry-
onic development. Morphological and histological analysis of
homozygous Notch1-deﬁcient embryos showed normal pattern for-
mation through the ﬁrst nine days of gestation. However, histological
analysis revealed widespread cell death after this stage, which was at-
tributed to disorganized and delayed somitogenesis [18,98]. To ex-
plore the role of NOTCH1 later in development, inducible Notch1
knockout were made. Mice, in which Notch expression was deleted
neonatally, were transiently growth retarded, severely deﬁcient in
thymocyte development and developed nodular hyperplasia in the
liver [20,77]. Inactivation of Notch1 in mouse skin resulted in epider-
mal and corneal hyperplasia, followed by the development of skin tu-
mors [72]. Additionally, activating NOTCH1 mutations are associated
with human T-cell acute lymphoblastic leukemia (T-ALL) [28]. These
ﬁndings implicate that in the adult stage NOTCH1 is still involved in
regulation of cell growth including both tumor suppressor and onco-
genic functions.
1.2.2. NOTCH2
Homozygous Notch2-deﬁcient embryos show developmental re-
tardation, widespread cell death and embryonic lethality before
ED11.5, but have, in contrast to Notch1 knockouts, normal somitogen-
esis [40]. Mice homozygous for a hypomorphic Notch2mutation show
defects in development of the kidney, heart and eye vasculature [66].
The human Allagille syndrome is associated with mutations in both
NOTCH2 and JAGGED1, and is characterized by growth retardation,
jaundice due to impairment of intrahepatic bile duct formation and
defective development of skeleton, heart, eyes and kidneys [68,97].
Mice doubly heterozygous for a hypomorphic Notch2 allele and a Jag-
ged1 null allele exhibit developmental abnormalities that resemble
the human Alagille syndrome. Heterozygous Notch2 mutants show
no abnormalities, while heterozygous Jagged1-deﬁcient mice exhibit
Table 1
Phenotypes of mice with targeted disruption of Notch pathway genes and DLK1.
Disrupted gene Phenotype
Notch1 (Swiatek, 1994) Embryonically lethal at ED10, widespread cell death, disturbed somitogenesis
Notch2 (Hamada, 1999) Embryonically lethal at ED11.5, widespread cell death, normal somitogenesis
Notch3 (Domenga, 2004) Viable and fertile, defects in postnatal maturation of vascular smooth muscle cells
Notch4 (Krebs, 2000) Viable and fertile; in combination with Notch1 deﬁciency severe vascular defects
Jagged1 (Xue, 1999) Embryonic lethal at ED10, defects in vascular remodeling of embryo and yolk sac
Jagged2 (Jiang, 1998) Perinatally lethal, craniofacial defects, skeletal defects, impaired thymic differentiation
Dll1 (Hrabe, 1997) Embryonically lethal at ED12, severe somite patterning defects, hyperplastic CNS
Dll3 (Dunwoodie, 2002) Viable with severe axial skeletal defects
Dll4 (Gale, 2004) Embryonic lethal from ED10.5, severe vascular remodeling defects in embryo and yolk sac
Dlk1 (Moon, 2002; Raghunandan, 2008;
Waddell, 2010; Puertas-Avendano, 2011)
Increased perinatal lethality, growth retardation, rib deformations, increased adiposity
Altered B-cell differentiation in spleen and bone narrow, reduced skeletal muscle mass, disturbed pituitary cell type development
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le's syndrome [67]. Furthermore, mice with a perinatal, liver-speciﬁc
complete elimination of Notch2 (Notch2ﬂ/ﬂ/Alb-Cretg/−) have a paucity
of bile ducts and jaundice, demonstrating that Notch2 signaling is re-
sponsible for the liver phenotype in Alagille's syndrome [37]. Recent-
ly, we investigated the effects of early embryonic elimination of
Notch2 in Notch2ﬂ/ﬂ/Alfp-Cretg/− (Notch2-cKO) mice and showed that
Notch2 is indispensable for biliary differentiation in mice [Falix et
al., Notch2 is required for cholangiocyte differentiation, Submitted].
Neonatal Notch2-cKO mice were severely jaundiced with livers
completely devoid of cytokeratin19-positive ductal structures.
mRNA levels of transcription factors involved in biliary development,
including Hnf6, Foxa1, Foxa2, Hhex, Hnf1β, Cebpα and Sox9were either
permanently or transiently decreased in postnatal Notch2-cKO livers,
indicating that during cholangiocyte differentiation, they lie down-
stream from Notch2 [Falix et al., Notch2 is required for cholangiocyte
differentiation, Submitted]. The above ﬁndings imply that mutations
in both NOTCH2 and JAGGED1 determine the severity of the pheno-
type of Alagille's syndrome.
1.2.3. NOTCH3 and NOTCH4
Notch3-null mice are viable and fertile without any apparent phe-
notypic abnormalities. However, adult Notch3 knockout mice show
obvious arterial defects due to abnormalities in differentiation and
maturation of vascular smooth-muscle cells [26,53]. In agreement
with a role for Notch3 in vascular development, mutations in the
EGF-repeats of the NOTCH3 gene in humans cause the cerebral auto-
somal dominant arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CADASIL) syndrome, leading to early stroke and
dementia [49]. Similar to Notch3, Notch4-null mice are viable and fer-
tile [53]. Involvement of Notch4 in vascular development is likely be-
cause its expression during embryonic development is restricted to
vascular endothelial cells [53]. Furthermore, Notch1/Notch4 double
knockouts show a more severe phenotype than Notch1 knockouts,
with extensive defects in angiogenic vascular remodeling that affect
the embryo, yolk sac and placenta at ED9.5 [53]. The aggravation of
the phenotype of Notch1 deﬁciency by Notch4 deﬁciency suggests a
partial functional redundancy of Notch4 for Notch1.
1.2.4. Notch canonical ligand knockouts
Homozygous disruption of the Notch ligands results in severe de-
velopmental defects. Jagged1-null mice exhibit defects in vascular
remodeling of the embryo and yolk sac and die at ED10 from exten-
sive hemorrhage [111]. Mice homozygous for a Jagged2 deletion die
perinatally because of defects in craniofacial- and limb morphogene-
sis with cleft palate, fusion of the tongue with the palatal shelves, syn-
dactyly (digit fusions) of the fore and hind limbs, and defective
thymus development [46]. Homozygous inactivation of Dll1 causes
severe defects in somite patterning and a hyperplastic CNS. Dll1-
deﬁcient mice become hemorrhagic after ED10 and die around
ED12 [42]. This implies that Dll1 expression is a prerequisite forNotch receptors to function during somitogenesis and CNS develop-
ment. In addition to DLL1, DLL3 is also involved in somitogenesis,
but Dll3-null mice are viable despite severe axial skeletal defects,
which probably result from delayed and irregular somite formation
[21,27]. In agreement, mutations in the human DLL3 gene are associ-
ated with spondylocostal dysplasia, that is, with similar vertebrocos-
tal defects as seen in Dll3-deﬁcient mice [13]. DLL3 differs structurally
from the other canonical DSL ligands (Fig. 2) and is considered a
Notch-signaling antagonist [21]. In agreement, Dll3 expression in
the presomitic mesoderm is unable to rescue the Dll1-deﬁcient so-
mite phenotype in mouse embryos [21]. Dll4 deﬁciency causes se-
vere vascular remodeling defects and embryonic lethality even in
the heterozygous condition. The phenotype of Dll4Lz/+ mice is rem-
iniscent of that reported for the homozygous Notch1/Notch4 double
knockout, suggesting that DLL4 is a major physiologic ligand for
these receptors and initiates their signaling during vascular devel-
opment [33]. Interestingly, mice lacking Jagged1 also exhibit a simi-
lar phenotype, which suggests an overlapping functional capacity
for JAGGED1 and DLL4.
The comparison of the phenotype of Notch receptor- and Notch-
ligand knockouts does not reveal extensively overlapping phenotypes,
apart from the described DLL4 and NOTCH1/4 vascular phenotypes. In
the case of ﬁxed ligand-receptor-pairs, one would expect that the deﬁ-
ciency of either the ligand or the receptor to cause a similar rather than
a different phenotype. The existence of non-overlapping phenotypes is,
on the other hand, also compatible with particular ligand-receptor
pairs, which, uponmodiﬁcation, affect a speciﬁc phenotype, but not an-
other. Possibly, therefore, both conditions are met if only a limited
number of permutations of ligands per receptor or vice versa are func-
tional. Alternatively, the interactions between receptors and ligands
could become unique by having additive effects (the Notch1/Notch4
double knockout has the same phenotype as the Dll4 knockout). The
relatively mild phenotype of Notch3 and Notch4 knockout mice sug-
gests functional redundancy with NOTCH1 and/or NOTCH2, but not
vice versa.2. DLK1, a noncanonical Notch ligand
2.1. Protein structure
Both the human DLK1 and the murine Dlk1 genes are maternally
imprinted, paternally expressed genes on chromosome 14 and 12 in
man and mouse, respectively [54].
Delta-like 1 homolog (DLK1), also known as Preadipocyte factor 1
(Pref-1) and Fetal antigen (FA1) [31,95], is an EGF-like membrane-
bound protein. It contains six tandem EGF-like repeats, a juxtamem-
brane region with a TACE (ADAM17)-mediated cleavage site, a trans-
membrane domain, and a short intracellular tail [109]. TACE-
mediated cleavage yields a soluble form of DLK1 with a molecular
weight of 50 kDa [109]. Alternative DLK1 splicing products have
been described in several mammalian species [1,23,69], which mostly
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sixth EGF repeat, resulting in membrane bound forms that sometimes
lack the TACE-sensitive cleavage site. The biological activity of these
splicing variants is yet not fully understood.
The structure and amino-acid sequence of the EGF repeats in DLK1
are closely related to those present in the canonical DLL ligands. How-
ever, DLK1 misses the conserved cryptic EGF repeat that is called the
DSL domain, which is present at the N-terminus of all canonical Notch
ligands (Fig. 1). For this reason, DLK1 is considered a DOS (co)ligand
[21,50,51]. Despite of the absence of a DSL domain, interaction be-
tween DLK1 and the NOTCH1 receptor was shown in the yeast GAL4
two-hybrid system. In this model system, pairs 10/11 and 12/13 of
the NOTCH1 EGF-like repeats interacted with DLK1 EGF repeats 1, 2,
5 and 6. [8]. NOTCH1 EGF-like repeats 11 and 12 are those reported
to interact with the DOS domain of canonical ligands [30,79,92,93].
DLK1 behaved as a negative regulator of NOTCH1 signaling in mesen-
chymal cell lines [8,74]. Furthermore, overexpression of murine Dlk1
in Drosophila altered the cellular distribution of Notch and inhibited
the expression of Notch target genes [11]. Recently, a new protein,
highly homologous to DLK1, named DLK2, has been discovered that
also interacts with the NOTCH1 receptor and inhibits Notch signaling
[73,89]. The inhibitory effect of DLK1 and DLK2 on Notch signaling
may be mediated by competition of with canonical ligands of the
DSL type for the binding site on the Notch receptor [25,74]. DLK1
was also shown to be involved in other signaling pathways, such as
the ERK/MAPK pathway [48,87,110,114] and the FGF-signaling path-
way [70]. In this review we will focus on its possible roles in the
Notch pathway.2.2. Expression during development
Dlk1 expression is widely distributed during mouse embryonic de-
velopment, with high expression in placenta, liver, adipose tissue, skel-
etal muscle, lung, vertebrae, and the pituitary- and adrenal gland(s)
[31,95,100,113]. In the adult, in contrast, expression becomes restricted
to (neuro)endocrine tissues like the pituitary gland, adrenal glands,
pancreas,monoaminergic neurons in the central nervous system, testes,
prostate and ovaries [15,31,43,44,55,81,102,113]. The reported expres-
sion pattern, together with its involvement in the Notch pathway, sug-
gests an important role for DLK1 during the maturation of several
tissues. However, Dlk-null mice display a relatively mild phenotype,
with increased perinatal lethality and growth retardation accompanied
by accelerated adiposity and developmental defects in the eyelids, ribs
and lungs, [71] as well as alterations in B-cell differentiation [78], and
pituitary cell type development [75]. Furthermore, muscle-speciﬁc
Dlk1-deletion resulted in disturbed muscle development and regenera-
tion [108].3. Role of DLK1 and Notch in different cellular systems
Despite of the reported inhibitory action of DLK1 on Notch sig-
naling in vitro [8,11,74], DLK1 involvement in Notch signaling during
development remains poorly understood. DLK1 is expressed in many
embryonic tissues, in which active Notch signaling was also reported
[17,35,36,38,39,90,103,104]. Postnatally, DLK1 expression has disap-
peared from most of these tissue, but is associated with pediatric
malignancies, such as hepatoblastoma, neuroblastoma and nephro-
blastoma [32,58,63,64], and some adult malignancies, such as myelo-
dysplastic syndrome, pituitary tumors, breast, colon and prostate
carcinoma [1,15,76,88,112]. Therefore, we discuss DLK1 expression
in relation to previously reported (interventions in) Notch signaling
during development in the above mentioned tissues (Section 2.2)
and provide a review of DLK1 and the Notch pathway in pediatric
malignancies.3.1. Adipogenesis
The best established function for DLK1/Pref1 is that of an inhibitor
of adipogenesis, as it prevents the differentiation of preadipocytes
into mature adipocytes [94–96,109]. DLK1 is highly expressed in mu-
rine preadipocytes, whereas its expression is completely abolished in
mature adipocytes. The 3T3L1 cell line is a frequently used murine
preadipocyte cell line to study the mechanism of adipocyte differenti-
ation after hormonal induction [19,95]. When 3T3L1 cells are induced
to differentiate into mature adipocytes, constitutive overexpression
of soluble DLK1 prevents adipogenic differentiation by inhibiting the
expression of the key transcriptional regulators of adipogenesis
Cebpα and Pparγ [94,95]. A direct effect of DLK1 on adipogenesis is
supported by the observed decrease in size of all adipose tissues, in-
cluding brown fat, in transgenic mice with adipocyte-speciﬁc overex-
pression of Dlk1 [56] and the increased adiposity and development of
fatty liver, with increased expression of lipogenic enzymes Fas and
Scd1, in mice lacking Dlk1 [71].
It is well possible that soluble and membrane-bound DLK1 differ
in function, as membrane-bound DLK1 is required for adipogenesis
in the 3T3L1 cell line [34]. Furthermore, overexpression of full-
length DLK1 (which generates both soluble and membrane-bound
DLK1) signiﬁcantly enhances adipogenic response in the mesenchy-
mal stem cell line C3H10T1/2 [74]. Additionally, we recently showed
that liver-speciﬁc overexpression of full-length Dlk1 resulted in a sex-
and diet-dependent increase of expression of Notch1 and the down-
stream Notch target Hes1, as well as adipogenic (Cebpα and Pparγ)
and lipogenic genes (Fas and Scd) in liver and adipose tissue. Dlk1-
overexpressing female mice on a high-fat diet were most sensitive
[Falix et al., Liver-speciﬁc overexpression of Dlk1 aggravates high fat
diet-induced steatosis in mice, Submitted].
The precise role of the Notch pathway in adipogenesis remains
controversial with reportedly both stimulatory and inhibitory roles
for Notch1 and Hes1 during adipocyte differentiation [8,35,74,82,83].
The effect of DLK1 on the Notch pathway during adipogenesis has
been studied in vitro in cell lines with (3T3L1 mouse preadipocyte
cell line) or without (Balb/c14 mouse ﬁbroblast cell line) endogenous
DLK1 expression [8]. Increased Dlk1 expression correlated with a de-
crease in Notch1 expression and a concomitant decrease in levels of
downstream target Hes1 in both cell lines, and resulted in inhibition
of adipogenesis in 3T3L1 cells [8]. Furthermore, in the mesenchymal
stem cell line C3H10T1/2, DLK1 overexpression also resulted in
Notch signaling inhibition [74]. These ﬁndings support the hypothesis
that DLK1acts as a negative regulator of Notch signaling. Interestingly,
constitutive Notch1 expression leading to increased Hes1mRNA levels
resulted in a decrease of Dlk1 mRNA levels and prevented adipocyte
differentiation in the 3T3L1 cell line [83]. Additionally, inhibition of
Notch1 expression prevented the potentiating effects of DLK1 on adi-
pogenesis in C3H10T1/2 cells [74]. It was, therefore, proposed that “a
proper balance of Notch signaling is critical for adipogenesis to pro-
ceed” and that “DLK1 might be a critical factor to control the proper
level of Notch signaling for cells to undergo adipogenesis” [8]. Collec-
tively, these ﬁndings indicate that DLK1 is not only an inhibitor of adi-
pogenesis, but that its role in adipogenesis is dependent on the
biological context.
3.2. Muscle development
The callipyge (CLPG) phenotype is an inherited skeletal muscle
hypertrophy of sheep. The CLPG mutation occurs in a highly con-
served motif between the imprinted Dlk1 and noncoding Gtl2 genes
[22]. This mutation causes abnormally high postnatal Dlk1 expression
in affected muscles, without altering its imprinted status [16]. Nor-
mally, Dlk1 expression in muscle is rapidly downregulated after
birth in both sheep and mice [16,31], and becomes re-expressed dur-
ing muscle injury and chronic myopathies [2,108]. Transgenic mice
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3F promoter have high Dlk1 expression in type myosin heavy-chain
type IIB (MYH4) muscle ﬁbers throughout pre- and postnatal devel-
opment. Compared to controls, these mice also show increased rela-
tive muscle mass and average ﬁber diameter in both the foreleg and
hind-leg muscles [22]. Deletion of Dlk1 in the myogenic lineage
resulted, on the other hand, in reduced skeletal muscle mass due to
a reduction in the number of myoﬁbers and Myh4 gene expression
and also impaired muscle regeneration. Dlk1 knockout inhibited the
expression of the muscle-determining transcription factor MyoD,
and facilitated the self-renewal of activated satellite cells. Conversely,
Dlk1 over-expression inhibited the proliferation and enhanced differ-
entiation of cultured myoblasts [108].These ﬁndings show that DLK1
participates in the regulation of muscle ﬁber growth during develop-
ment and that postnatally persisting Dlk1 expression in skeletal mus-
cle contributes directly to the muscular hypertrophy observed in
CLPG sheep.
Notch signaling inhibits myogenic differentiation by suppression
of MyoD expression, which is critical for the proper expansion of
muscle progenitors during development [12,90,104,105]. Mice carry-
ing either a hypomorphic allele of the Notch ligand Dll1 or a
myocyte-speciﬁc deletion of the Notch downstream transcription
factor Cbf1 both display severe muscle hypotrophy due to uncon-
trolled premature differentiation of the muscle progenitor cell pool,
with increased expression of myogenic regulatory factors MyoD
and Myogenin and a reduced number of muscle progenitor cells
[90,105]. Comparison of the DLK1 and Notch muscle phenotypes
shows that DLK1 and NOTCH have opposite effects on myogenesis,
which is compatible with the putatively inhibitory effect of DLK1
on Notch signaling.
3.3. Liver development
Dlk1 is one of the most abundant transcripts in mouse ED14.5
liver, while expression is rapidly downregulated thereafter to become
undetectable just before birth [100]. DLK1-positive fetal liver cells
show higher proliferative potential compared to the DLK1-negative
cell population and are able to differentiate into both the hepatocyte
and cholangiocyte lineages [100], which implies that DLK1-positive
liver cells are still hepatoblasts. Notch1, Notch2, and Jagged1 are
expressed in prenatal liver, with a peak just prior to birth. Immediate-
ly after birth, their expression returns again to basal levels [61,99].
Notch2 and Jagged1 are necessary for appropriate bile duct devel-
opment [37,67] [Falix et al., Notch2 is required for cholangiocyte dif-
ferentiation, Submitted]. Recently, NOTCH1 was shown to stimulate
both pre- and postnatal bile-duct proliferation [116]. Overexpression
of the NICD in in-vitro differentiated DLK1-positive hepatoblasts
resulted in downregulation of hepatocyte-marker genes (albumin,
CPS, TAT) and, subsequently, in upregulation of cholangiocyte marker
genes (CK7, CK19, HNF1ß, integrin ß4) [99]. Notch signaling may,
therefore, confer the capacity to differentiate along the cholangiocyte
lineage upon hepatoblasts [99]. The rapid downregulation of Dlk1 ex-
pression just prior to birth, which coincides with the peak in Notch1,
Notch2 and Jagged1 expression, is also compatible with induction of
hepatoblast maturation along the cholangiocyte lineage due to activa-
tion of NOTCH1/2 receptor signaling. In agreement, we recently
showed that Notch2 is indispensable for cholangiocyte differentiation
and that its absence does not affect Dlk1 expression [Falix et al.,
Notch2 is required for cholangiocyte differentiation, Submitted].
3.4. Branching morphogenesis in lung and pancreas
In the developing lung and pancreas, Dlk1 expression is restricted
to the distal growing epithelia and the surrounding mesenchyme
[113]. In agreement, we recently demonstrated that DLK1 protein in
the developing lung and pancreas is only found in the distal parts ofthe tubular trees and the surrounding mesenchyme, where branching
morphogenesis takes place [Falix et al., DLK1 expression during
mouse embryonic development provides more insights in its func-
tion, Submitted]. Branching morphogenesis is a characteristic process
in developing tubular structures that is dependent on interactions be-
tween the growing epithelial bud and the surrounding mesenchyme
[41]. Notch signaling does regulate branching morphogenesis in the
developing lung [103]. Disruption of Notch signaling during the initial
stages of murine lung development results in a dramatic expansion of
the population of distal progenitors and in prevention of the forma-
tion of proximal airway structures [103]. Constitutive Notch signaling
by contrast, prevents the differentiation of alveolar (distal) epitheli-
um and induces the development of cysts at the location of the distal
airways, which are composed of cells that express markers of proxi-
mal airway epithelium [38].
Analogous to lung development, disruption of Notch signaling
during pancreatic development led to pancreatic hypoplasia due to
depletion of pancreatic epithelial precursors [3,45], whereas consti-
tutive overexpression of Notch signaling led to impaired branching
of the pancreatic epithelium with formation of cyst-like structures
without exocrine cells and repression of endocrine development
[39], that is, suppression of differentiation of distal epithelial cells.
These observations indicate that Notch signaling regulates branching
and the establishment of a proximal–distal gradient in cell fate dur-
ing gland formation in mammals, with probably a regulatory func-
tion for DLK1.
3.5. Pituitary gland development
DLK1 expression in developing mouse fetuses declines after
ED16, including the pituitary gland, but this organ is one of the
few that remains positive for DLK1 expression, also after birth
[75,113]. During pituitary development in the mouse, between
ED11 and ED14 the ﬁrst pituitary-speciﬁc cell types are formed:
thyrotroph and corticotroph cells. Thereafter, around ED15 somato-
troph, gonadotroph and lactotroph cells are formed with completion
of cell speciﬁcation and differentiation on ED17 [91,107]. This time
point coincides with the signiﬁcant overall decrease in DLK1 expres-
sion, also in the pituitary gland. The temporal expression of canoni-
cal Notch pathway members in the pituitary is comparable to that of
DLK1, with an overall decrease of both Notch receptor mRNAs and
ligands in the late embryonal period [115]. Interference with Notch
signaling results in premature differentiation of the early differenti-
ating corticotropic lineage and inhibition of differentiation of the
later differentiating somatotropic and gonadotropic lineages. In con-
trast, sustained Notch signaling in somato- and lactotropic precur-
sors results in a reduction of the prevalence of these cell
populations. These ﬁndings show that Notch signaling prevents con-
version of the late-arising cell lineages to early-born cell lineages
and that attenuation of Notch signaling later in pituitary develop-
ment is required for proper terminal differentiation of the lineages
[115]. The observed expression pattern of DLK1 in the developing pi-
tuitary suggests that DLK1 may be a player in the regulation of dif-
ferentiation of pituitary cell types by modulating Notch signaling
activity. In agreement with such a role, the pituitary of adult Dlk1
knockout mice contains a signiﬁcantly lower number of somato-
trophs and a reduction in cell-speciﬁc gene expression in gonado-
trophs compared to wild-type mice [75].
4. DLK1 and Notch in pediatric malignancies
Pediatric tumors like neuroblastoma, hepatoblastoma, and
nephroblastoma (Wilms tumor) are believed to arise from cellular
populations that have not completed the process of differentiation.
In agreement, signal-transduction pathways involved in embryonic
development, like the Wnt/β-catenin pathway, are frequently
993F.A. Falix et al. / Biochimica et Biophysica Acta 1822 (2012) 988–995upregulated in these tumors [14,62]. Recently, both DLK1 and the
Notch pathway have also been associated with these pediatric malig-
nancies [24,32,59,63,64,117].
4.1. Neuroblastoma
Neuroblastoma, an embryonic tumor originating from immature
sympathetic neuroblast, displays a remarkable spectrum of clinical
and biological behavior, ranging from spontaneous regression of me-
tastases to rapid and fatal progression despite intensive therapy [58].
High expression of DLK1 and the NOTCH3 receptor was reported in
subsets of neuroblastoma tumors and cell lines [59]. DLK1 expression
correlated perfectly with dopamine β-hydroxylase (DBH) expression,
an enzyme which is normally highly expressed in the chromafﬁn cells
of the adrenal medulla and converts dopamine to noradrenaline [59].
During early embryonic development, DLK1 expression is detected
throughout the adrenal gland, while later during development ex-
pression becomes restricted to the chromafﬁn cells, one of the few
cell types that maintains postnatal DLK1 expression [44,113]. Inter-
estingly, the reported DLK1 expression in neuroblastoma cell lines
was inversely correlated to NOTCH3 expression [59]. Therefore, it
was suggested that overexpression of NOTCH3 in neuroblastoma cell
lines corresponds with early precursor stages, whereas overexpres-
sion of DLK1 reﬂects differentiation arrest in a relatively late stage
of the chromafﬁn lineage [59].
4.2. Hepatoblastoma
Hepatoblastoma, a malignant pediatric liver tumor, is believed to
derive from hepatoblasts, because of the stem-cell like appearance
of the hepatoblastoma cells [85,86,106]. Hepatoblastomas are charac-
terized by a diversity of epithelial and often mesenchymal patterns of
differentiation, with some epithelial variants that morphologically re-
semble embryonic or fetal hepatocytes [65,84]. Recently, increased
expression of DLK1was found to be a consistent feature among hepa-
toblastomas [14,24,63,64]. DLK1 was signiﬁcantly elevated in all his-
tological subtypes when compared to normal liver, sometimes even
higher than in fetal liver [63]. In fact, we recently showed that
serum DLK1 levels were signiﬁcantly elevated in hepatoblastoma pa-
tients compared to age-matched controls, even in the youngest pa-
tients, in whom serum α-fetoprotein levels are often in the same
range as the still elevated control levels [29].These ﬁndings make
DLK1 a candidate serum marker to diagnose hepatoblastoma in the
young infant age group.
NOTCH2 receptor expression was increased in 92% of hepatoblas-
tomas compared to normal liver tissue. HES1, the best studied Notch
downstream target, was also elevated in hepatoblastomas, especially
in the pure fetal subtype [60,63]. These ﬁndings indicate that active
Notch signaling occurs in hepatoblastoma tumors and might regulate
tumor growth. The abrupt disappearance of DLK1 expression in late
liver development, together with its re-appearance in hepatoblas-
toma, suggest a role for DLK1 in hepatoblastoma pathogenesis. How-
ever, we showed recently that transgenic mice with hepatocyte-
speciﬁc overexpression of Dlk1 do not develop liver tumors up to
1.5 years of age [Falix et al., Liver-speciﬁc overexpression of Dlk1 ag-
gravates high fat diet-induced steatosis in mice, Submitted]. These
ﬁndings imply that increased Notch signaling, probably via the
NOTCH2 receptor, is more likely to be involved in the pathogenesis
of hepatoblastoma.
4.3. Wilms tumor
Nephroblastoma is a pediatric tumor of the kidney, also known as
Wilms tumor. Loss of imprinting (LOI) of the reciprocally imprinted
H19/IGF2 domain is a common feature of Wilms tumor, where H19
is a non-coding gene and IFG2 an important regulator of fetal growth[32,80]. The DLK1 gene is similarly arranged by formation of an
imprinted domain with a noncoding gene called GTL2 [32]. DLK1 ex-
pression is absent in developing kidney, but interestingly, high DLK1
expression was detected in 11 out of 30 Wilms tumors with promi-
nent myogenic differentiation and blastemal components. The im-
printing status of the DLK1/GTL2 domain was shown to be retained
[32]. Since DLK1 is associated with muscular growth and develop-
ment [22], DLK1 expression in Wilms tumor may only reﬂect the
presence of myogenic differentiation in a signiﬁcant proportion of
the tumor cells (see Section 3.2).
5. Conclusion
In this review we summarized Notch signaling pathway during
development and disease, and discussed the relation of the noncano-
nical Notch ligand DLK1 with Notch signaling in developing organs
and pediatric malignancies. DLK1 is expressed in many organs prior
to and during terminal differentiation of the parenchymal cells and
becomes abolished thereafter. DLK1 seems to be involved in develop-
mental processes, such as branching morphogenesis (lung, pancreas)
and terminal differentiation (adipose tissue, muscle, liver, pituitary),
with as common features among organs stimulation of growth and
inhibition of differentiation. Based on its expression pattern during
development and adipogenesis, and its effects upon experimental in-
terventions, DLK1 appears to function as an inhibitory modulator of
Notch signaling, either by competing with canonical ligands or by di-
rect interaction with the NOTCH(1) receptor, or both.
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